摘要:
Methods for selection of compounds for treatment of obesity, compounds selected by the disclosed methods, and methods of treatment of obesity, wherein a selective melanocortin-4 receptor compound is identified, which compound is further characterized in that it attenuates the binding of both an agonist, including alpha-melanocyte stimulating hormone, and an inverse agonist, including agouti-related protein, to a melanocortin receptor, including melanocortin-4 receptor.
摘要:
The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists or inverse agonists of Dynorphin A and its analogues. The assays are based upon the binding of Dynorphin A and its analogues to the rat and human MAS receptors.
摘要:
The present invention relates to a biomarker for the efficacy of appetite suppressant drugs given to humans or other mammals for the treatment of obesity. It further relates to a novel method of determining the efficacy of a test compound given to a subject for the treatment of obesity, wherein the test compound is an appetite suppressant which does not stimulate the release of serotonin. It also relates to a method for following the progress of a therapeutic regime designed to alleviate obesity and to a method for determining the appropriate dosage of an appetite suppressant given to a subject for the treatment of obesity.
摘要:
The present invention relates to novel dihydroisoquinolinone (DHQ) derivative compounds of formula (I): wherein R1 to R7, X, Y, Z, b, c and d have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing DHQ derivative compounds.
摘要:
The present invention relates to Agouti-related protein (AGRP) analogues and methods of use. The invention is exemplified by chemical synthesis and detectable labeling of AGRP analogues, and their novel exploitation in a variety of different assays and screens. The inventions find use, for example, in drug discovery and diagnostics related to feeding disorders including wasting syndromes, obesity, and other disorders related to hypothalamic control of feeding.
摘要:
Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising: • determining the level of Pro-Enkephalin or fragments thereof including Leu-Enkephalin and Met-Enkephalin of at least 5 amino acids in a bodily fluid obtained from said female subject; and • correlating said level of Pro-Enkephalin or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.
摘要:
Screening methods of use in identifying agents that affect caloric intake, food intake, appetite, and energy expenditure are disclosed herein. These methods are used to identify agents of use in treating obesity, or that can be used to decrease the weight of a subject. These methods can also be used to identify agents of use in treating anorexia or cachexia and can be used to increase appetite and to increase the weight and lean body mass of a subject.
摘要:
The present invention relates to Agouti-related protein (AGRP) analogues and methods of use. The invention is exemplified by chemical synthesis and detectable labeling of AGRP analogues, and their novel exploitation in a variety of different assays and screens. The inventions find use, for example, in drug discovery and diagnostics related to feeding disorders including wasting syndromes, obesity, and other disorders related to hypothalamic control of feeding.